An interesting article explaining how Israel’s CytoReason (see here previously) is using AI and big data from the medical companies themselves to help reduce the cost and time required to bring a new remedy to market. https://nocamels.com/2024/02/using-ai-made-models-to-find-cures-for-disease/

Israel’s CytoReason (see here previously) is partnering France’s Sanofi to identify novel therapies to treat Inflammatory Bowel Disease (IBD). Sanofi will pay CytoReason millions of dollars to use the Israeli startup’s computational AI-discovery disease model platform. https://www.timesofisrael.com/sanofi-extends-cooperation-with-israels-cytoreason-for-bowel-disease-drug-discovery/

Israel’s Technion Institute is establishing the Zimin Institute for AI Solutions in Healthcare. Headed by Professor Shai Shen-Orr (founder of CytoReason), it will research human health and medicine, using big data and computational learning. It aims to benefit hospitals, new … Continue reading →

Israel’s CytoReason (see here previously) has added SPI (part of Japanese giant Sumitomo) to its growing list of partners.  SPI will use CytoReason’s unique immune focused machine learning platform and represent CytoReason in the Japanese market – the third largest … Continue reading →

Israel’s CytoReason (see here previously) is partnering Swiss multinational Ferring to find new treatments for patients with inflammatory bowel disease (IBD). CytoReason’s AI technology will enable the joint building of models of diseased cells on which therapies will be tested. … Continue reading →

Another exciting webinar (see previous) from Technion UK featuring Technion Professor Shai Shen-Orr (founder of CytoReason) one of the leading Israeli researchers into the mysteries of the immune system. Also featured is Professor Ester Sager who is developing biosensors to … Continue reading →

I reported previously on Israel’s CytoReason which uses an Artificial Intelligent learning model to discover treatments related to the human immune system. CytoReason has just partnered with Pfizer – its fifth alliance with a major company. http://nocamels.com/2019/01/drug-discovery-cytoreason-pfizer/ https://docs.wixstatic.com/ugd/216dd2_5d94d4baffe5460d80e3fcbe79c5c1ea.pdf